Clinical data disappointments and third-quarte results cast a shadow on the BioWorld Neurological Diseases Index, closing November with an 18.37% year-to-date decline. This marks a slight improvement from its low point in October, down 23.79%, in contrast to the previous year’s upward trend, which it concluded with an 18.24% increase.

Intracellular chloride levels are crucial for physiological brain development and correct functioning. On the other hand, aberrant expression of chloride importer NKCC1 (basolateral Na-K-Cl symporter, SLC12A2) and exporter KCC2 (K-Cl cotransporter 2, SLC12A5) is involved in neurodevelopmental and neurologic conditions, including mesial temporal lobe epilepsy (MTLE), among others, leading to an imbalance between excitatory and inhibitory signals.

Rewalk Robotics Ltd. has integrated advanced sensing technologies and artificial intelligence (AI) into its latest exoskeleton prototype to enable autonomous decisionmaking. This milestone, coupled with Rewalk’s capabilities, holds enormous potential to create a new generation of exoskeletons that are more intuitive and respond to real-world conditions that users encounter daily, Rewalk CEO Larry Jasinski told BioWorld.

Nurexone Biologic Inc. has reported results from laboratory tests of its secondary two proprietary sequences, showing promise for the treatment of spinal cord injuries.